Editorial Standards & Clinical Review

Who develops the content.

The clinical author develops the educational framework, narrative, interpretation and teaching structure for an article — deciding what a reader needs to understand a topic and in what order, and drafting the explanation of the underlying pharmacology, physiology and clinical context.

How claims are checked.

Clinically consequential claims — statements about safety, efficacy, regulatory status, or comparative outcomes — undergo evidence verification against a preferred source hierarchy, generally in this order:

• Regulatory agencies (for example, FDA statements and labeling)
• Professional clinical guidelines and society position statements
• Systematic reviews and meta-analyses
• Peer-reviewed primary research, including randomized and observational studies
• Authoritative laboratory-medicine and pharmacology references

Evidence is not treated as one undifferentiated category. A pharmacologic mechanism, an observational association, a randomized clinical trial finding, and a demonstrated clinical outcome are different kinds of evidence with different strength, and our articles are written to say which kind of evidence supports a given statement rather than blending them into a single confident-sounding claim.

Where a claim cannot be adequately verified during editorial development, it is not presented as established fact. Instead, it remains visibly flagged — marked for further review — so a reader can see exactly which parts of an article are fully sourced and which remain open questions.

A separate, distinct function — and two possible forms.

Authorship, evidence verification, and medical review by a qualified clinician are separate functions, performed at different stages and, for medical review specifically, by someone other than the article's clinical author. Before an article is designated as medically reviewed, an appropriately qualified clinician is expected to evaluate:

• Clinical accuracy of the content as written
• Fair representation of the cited evidence, without overstatement in either direction
• Whether important limitations and uncertainty are clearly disclosed
• Safety and efficacy claims specifically
• Regulatory statements, where relevant
• Absence of inappropriate individualized medical advice

We distinguish two forms of this review, based on whether the reviewing clinician has a relevant relationship with Pharmaprodia:

• External Medical Review — performed by a qualified clinician who is not the article's author but who may have a professional, financial, referral, prescribing, consulting, research, or other relevant relationship with Pharmaprodia. Where that is the case, the relevant relationship is disclosed alongside the review.
• Independent Medical Review — performed by a qualified clinician for whom no material relationship of that kind exists that would reasonably call the review's independence into question.

Neither label is a guarantee of objectivity by itself. The distinction exists so a reader can see, alongside a reviewer's name and credentials, whether a relevant relationship has been disclosed for that specific review.

What we disclose, and why.

Relevant professional or financial relationships should be disclosed whenever they could reasonably affect how a reader interprets clinical content. Pharmaprodia is a compounding pharmacy, and we state that plainly here rather than leaving it implicit.

That commercial context does not change the editorial requirement to distinguish evidence from opinion, or to avoid unsupported claims that compounded therapies are inherently safer, more effective, or superior to FDA-approved therapies. Where our own Clinical Education articles discuss compounded formulations, they are held to the same evidentiary standard as any other claim — including, where the evidence indicates a limitation of a compounded approach, saying so.

This same disclosure standard applies to medical reviewers. As described in the section above, where a reviewing clinician has a relevant professional, financial, referral, prescribing, consulting, or research relationship with Pharmaprodia, that relationship is disclosed alongside their review and the review is labeled "External Medical Review" rather than "Independent Medical Review."

How we handle errors.

Clinically meaningful errors discovered after publication are corrected. Where appropriate, that means:

• Updating the article text itself
• Updating the "last reviewed" date to reflect the correction
• Documenting material corrections so the change is not silent
• Repeating external or independent medical review when a correction materially changes the clinical interpretation of the article

This policy describes our editorial intent; the specific tooling to display a public correction log is not yet built into this library.

Content is not static.

Clinical guidance and evidence evolve. Published articles are expected to undergo periodic review as circumstances warrant, including:

• New professional-society guidelines relevant to the article's topic
• Important regulatory changes (for example, a new FDA approval or safety communication)
• Important new evidence, such as a major trial or systematic review
• Material changes in clinical consensus

We have not adopted a fixed mandatory review interval (such as an annual cycle); re-review is triggered by the developments above rather than by the calendar alone.

What this library is — and isn't.